DNAe to Present New Data on LiDia BSI, its Rapid Blood-to-Result Diagnostic Test at the Association of Molecular Pathology Annual Meeting

London, UK and Carlsbad, CA, USA – 7 November 2017 – DNA Electronics Ltd, the inventor of semiconductor based genomic analysis technologies, and the developer of a new, game-changing test for bloodstream infections that can lead to sepsis will be presenting new data at the Association for Molecular Pathology (AMP) Annual Meeting 2017 in Salt Lake City, USA from the 16^th to 18^th November.

Poster Presentation – ID31

Title: Rapid Diagnosis of Bloodstream Infections Through Identification of Pathogens and Resistance Markers Directly from Whole Human Blood at 1 CFU/ml
Authors: N. Casali, T. Mach, Z. Lang, F. Paillier, B.A. Brown, L-J. Clarizia, A. Bahrami, S. Barakat, N. Brown, M. Davila, A. Day, J. Gallagher, C. Icely, J. Killpack, S. McBader, G. McCabe, M. Norvell, S. Pradhan, N. Shublaq, A. Swanson, S. Tarver, N. Viswanathan, J.J. Ward, J. Wood, L. Xiong, C.J. McElgunn, R. Sahoo, D.W.N. Edington, D.A. Davidson, C. Toumazou
Location: Infectious Diseases Poster Session, Exhibit Hall
Time: 9:45 am – 10:45 am, Saturday, 18^th November

Drs. Nicola Casali, Nour Shublaq and Francois Paillier will be available to discuss the data.

Dr Steve Allen, CEO of DNAe Group Holdings, commented: “As we move our LiDia™ BSI rapid blood-to-result diagnostic test towards commercial launch, we are pleased to present, for the second year running, key data at the AMP Annual Meeting, one of the premier annual gatherings in the field of molecular diagnostics. This is an exciting time for DNAe as we prepare to CE mark LiDia™ BSI in 2018, to enable us to bring this urgently needed test to market.”